Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Endoxifen - Atossa Therapeutics

Next Previous
Drug Profile

Endoxifen - Atossa Therapeutics

Alternative Names: (Z)-endoxifen; Z-endoxifen - Atossa Therapeutics

Latest Information Update: 08 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atossa Genetics
  • Developer Atossa Therapeutics; Weill Cornell Medicine
  • Class Antineoplastics; Methylamines; Phenyl ethers; Small molecules; Stilbenes
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Ductal carcinoma; HER2 negative breast cancer
  • Preclinical Triple negative breast cancer
  • No development reported Gynaecomastia; Ovarian cancer

Most Recent Events

  • 06 Oct 2025 Atossa Therapeutics plans NDA submission to US FDA
  • 06 Oct 2025 Efficacy data from a phase II EVANGELINE trial in HER2-negative-breast-cancer trial released by Atossa Therapeutics
  • 08 Sep 2025 Atossa Therapeutics plans a Type C meeting with the US FDA to discuss regulatory strategies for development of low-dose (Z)-endoxifen for Breast cancer risk reduction in 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top